Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746297 | 0.89 | PIK3CG (0.46) | PIK3CGIGF1REGFRCYP1A2HSD17B10 | |
| SCHEMBL3734583 | 0.86 | CSF1R (0.54) | WNT3ACSF1REGFRCYP1A2CYP3A4 | |
| SCHEMBL13019092 | 0.76 | CSF1R (0.54) | WNT3ACSF1REGFRCYP1A2CYP3A4 | |
| SCHEMBL3731334 | 0.74 | EGFR (0.51) | PIK3CGWNT3ACSF1REGFRCYP1A2 | |
| SCHEMBL13019110 | 0.72 | APP (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL13043138 | 0.72 | MKNK2 (0.43) | PIK3CGCSF1REGFRMAPK1 | |
| SCHEMBL3737557 | 0.72 | MKNK2 (0.53) | PIK3CGALDH1A1LMNAMAPK1 | |
| SCHEMBL3746874 | 0.71 | PIK3CG (0.40) | PIK3CGHSD17B10ALOX15ALDH1A1LMNA | |
| SCHEMBL13019105 | 0.71 | MKNK2 (0.42) | PIK3CGCSF1REGFRMAPK1 | |
| SCHEMBL24674165 | 0.70 | MET (0.46) | WNT3ACSF1REGFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885WNT3A 3359/4885CSF1R 1406/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885WNT3A 3359/4885CSF1R 1406/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885WNT3A 3359/4885CSF1R 1406/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885WNT3A 3359/4885CSF1R 1406/4885 |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885WNT3A 3359/4885CSF1R 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.